

**Supplementary Table S1.** The country wise distribution of glaucoma cases reported to the CDC VAERS.\*

	Vaccine		
	ad26.cov2.s	BNT162b2	mRNA-1273
	Count	Count	Count
Australia	0	1	0
Austria	0	1	0
Belgium	1	6	0
Czech Republic	0	3	0
Denmark	0	0	1
Estonia	0	4	0
Finland	0	2	0
Foreign (non-specific)	0	1	2
France	1	18	1
Germany	1	10	1
Great Britain	0	12	0
Greece	0	2	0
Ireland	0	1	0
Italy	0	8	1
Japan	0	13	0
Latvia	0	1	0
Lithuania	0	1	0
Netherlands	0	3	1
Norway	0	0	2
Philippines	0	1	0
Poland	0	1	0
Portugal	0	2	0
Sweden	0	1	0
Taiwan	0	2	2
Unknown	0	3	2
USA	1	33	14

\* The state-wise distribution of the cases in the United States was included in the VAERS database. The origin of a report from foreign (non-US) countries was identified on the basis of unique identification number assigned by the reporting regulatory body or vaccine manufacturer.

**Supplementary Table S2.** State-wise crude reporting rate of glaucoma per million doses of COVID-19 vaccinations

	<b>Glaucoma cases per million doses*</b>		
	<b>BNT162b2</b>	<b>mRNA-1273</b>	<b>Ad26.COV2.S</b>
<b>Alabama</b>	0.00	0.37	0.00
<b>Arizona</b>	0.29	0.00	0.00
<b>California</b>	0.09	0.00	0.43
<b>Colorado</b>	0.32	0.00	0.00
<b>Georgia</b>	0.00	0.34	0.00
<b>Illinois</b>	0.07	0.25	0.00
<b>Kentucky</b>	0.28	0.37	0.00
<b>Maryland</b>	0.14	0.00	0.00
<b>Massachusetts</b>	0.12	0.00	0.00
<b>Michigan</b>	0.00	0.16	0.00
<b>Mississippi</b>	0.45	0.00	0.00
<b>Missouri</b>	0.18	0.31	0.00
<b>Montana</b>	1.17	0.00	0.00
<b>New Jersey</b>	0.20	0.00	0.00
<b>New York</b>	0.04	0.00	0.00
<b>North Carolina</b>	0.30	0.00	0.00
<b>North Dakota</b>	1.60	0.00	0.00
<b>Ohio</b>	0.19	0.00	0.00
<b>Pennsylvania</b>	0.38	0.00	0.00
<b>South Carolina</b>	0.23	0.00	0.00
<b>Tennessee</b>	0.00	0.26	0.00
<b>Texas</b>	0.04	0.00	0.00
<b>Virginia</b>	0.00	0.34	0.00
<b>Washington</b>	0.00	0.18	0.00
<b>West Virginia</b>	0.68	0.85	0.00
<b>Wisconsin</b>	0.33	0.26	0.00

\*Vaccine data from Centers for Disease Control and Prevention on April 30, 2022

**Supplementary Table S3.** Therapeutic interventions reported in patients diagnosed with glaucoma post-COVID-19 vaccination

	Frequency	%
Brimonidine	5	3.1
Dorzolamide	6	3.7
Eye drops (not specified)	18	11.2
Laser iridotomy	18	11.2
Mannitol	2	1.2
Shunt/Valve placement	4	2.5
Surgery (not specified)	7	4.3
Timolol	11	6.8
Trabeculectomy	2	1.2
Travoprost/Latanoprost	2	1.2
No/unknown intervention	86	53.4